4-hydroxy-2,4-diphenyl-acetoacetic acid-lactone | 22884-83-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 内酯类
• 英文名称: 4-hydroxy-2,4-diphenyl-acetoacetic acid-lactone
• 英文别名: 4-Hydroxy-2,4-diphenyl-acetessigsaeure-lacton；3,5-diphenyl-2,4(3H,5H)-furandione；3,5-Diphenyloxolane-2,4-dione
• CAS: 22884-83-9
• 化学式: C₁₆H₁₂O₃
• 分子量: 252.269
• InChiKey: UAHQEMABSWATQJ-UHFFFAOYSA-N

物化性质

• 熔点：
  203-206 °C
• 沸点：
  488.1±45.0 °C(Predicted)
• 密度：
  1.254±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-hydroxy-2,4-diphenyl-acetoacetic acid-lactone 、 alkaline earth salt of/the/ methylsulfuric acid 生成 苯甲酰甲酸
  参考文献：
  名称：

  Kohler, Journal of the American Chemical Society, 1928, vol. 50, p. 224

  摘要：

  DOI：
• 作为产物：
  描述：

  3-hydroxy-4-oxo-2,4-diphenyl-butyric acid 在 盐酸 作用下， 生成 4-hydroxy-2,4-diphenyl-acetoacetic acid-lactone
  参考文献：
  名称：

  Kohler, Journal of the American Chemical Society, 1928, vol. 50, p. 224

  摘要：

  DOI：

文献信息

• Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof
  申请人：Brown R. Truman

  公开号：US20060089316A1

  公开（公告）日：2006-04-27

  Disclosed are methods of using various compounds, which are known to bind to 3-deoxyglucosone (3DG) or precursors thereof, in order to reduce a susceptibility to tumor formation and/or to prevent or delay onset of tumor formation induced by 3DG and its precursors. Also disclosed is the reduction of 3DG levels in high fructose corn syrop so that the high fructose corn syrup is less likely to induce tumor formation.

  公开了使用各种已知与3-脱氧葡萄糖酮（3DG）或其前体结合的化合物的方法，以减少对肿瘤形成的易感性和/或预防或延迟由3DG及其前体诱导的肿瘤形成。还公开了降低高果糖玉米糖浆中3DG水平的方法，以使高果糖玉米糖浆不太可能诱导肿瘤形成。
• 12. The synthesis of 2-cyclohexyl-6-methylheptane
  作者：D. H. Hey、D. S. Morris

  DOI：10.1039/jr9480000048

  日期：——
• Ketene Acetals. XXVII. The Bromination of Various Ketene Acetals
  作者：S. M. McElvain、William R. Davie

  DOI：10.1021/ja01127a057

  日期：1952.4
• Optically Active Ketonic Beta Lactones
  作者：Charles L. Bickel

  DOI：10.1021/ja01210a008

  日期：1946.6
• Point of care and central laboratory determinations of the aPTT are not interchangeable in surgical intensive care patients
  作者：Martine Ferring、Guido Reber、Philippe de Moerloose、Paolo Merlani、Marc Diby、Bara Ricou

  DOI：10.1007/bf03020384

  日期：2001.12

  Purpose: The objective of the study was to compare a bedside whole blood activated partial thromboplastin time (aPTT) performed by a point of care (POC) apparatus (CoaguCheck (R) Pro) in surgical intensive care (SIC) patients with a conventional aFTT obtained from the central laboratory.Methods: The prospective concomitant measurements of the two aPTT were performed in 233 samples from 46 consecutive patients admitted after cardiovascular or major abdominal surgery.Results: Inter-operator, inter-instrument and inter-cartridge variability of the new device measured in three healthy volunteers and in nine patients in stable condition (controls) was low (F test: P=0.86). The agreement by Bland and Altman between POC and central laboratory aPTT (-20.2 +/- 18.8 sec) was not satisfactory. The agreement between POC and central laboratory aPTT in patients after surgery was worst (-17 +/- 33.1 sec). Heparin treatment or timing of blood sampling after intensive care admission (< 48 hr Ys > 48 hr) did not influence the agreement. The correlation between POC or central laboratory aPTT and anti-factor Xa activity was poor (r(2) 0.077 and 0.181 respectively). The test which correlated the best to heparin doses was anti-factor Xa activity (r(2) 0.714),Conclusion: POC aPTT and central laboratory aPTT showed a poor agreement in SIC patients admitted after surgery, although in healthy volunteers or in control patients, this agreement was better. The best test to monitor heparin treatment in this setting was anti-factor Xa activity.